Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Glaxosmithkline Plc (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 99,521,584
  • Shares Outstanding, K 2,480,598
  • Annual Sales, $ 41,140 M
  • Annual Income, $ 4,836 M
  • 60-Month Beta 0.74
  • Price/Sales 2.42
  • Price/Cash Flow 9.65
  • Price/Book 22.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.65
  • Number of Estimates 3
  • High Estimate 0.68
  • Low Estimate 0.62
  • Prior Year 0.77
  • Growth Rate Est. (year over year) -15.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.43 +4.10%
on 05/31/19
40.43 -1.05%
on 06/12/19
+0.55 (+1.38%)
since 05/17/19
3-Month
38.43 +4.10%
on 05/31/19
42.20 -5.20%
on 04/02/19
-0.63 (-1.54%)
since 03/15/19
52-Week
36.41 +9.87%
on 12/06/18
42.32 -5.47%
on 07/20/18
-1.43 (-3.46%)
since 06/15/18

Most Recent Stories

More News
Glaxo Inks Genome Research Deal With University of California

Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.

VRTX : 173.78 (+2.09%)
EDIT : 22.42 (+3.18%)
GSK : 39.96 (-0.40%)
NTLA : 14.89 (+7.12%)
SmallCap Sentinel: As Fears Abate, an Array of Positive Factors Align for Drug Makers

The fears present in the 2018 market for drug makers... price ceilings and regulatory assaults... may have been exaggerated. In fact, a market under siege in 2018 has had a more than solid year. Recent...

ABT : 81.90 (-0.39%)
JNJ : 139.59 (-0.36%)
GSK : 39.96 (-0.40%)
INNV : 1.2500 (-16.67%)
PRGO : 43.85 (+1.55%)
Zai Lab Announces Approval to Commercialize ZEJULA (Niraparib) in Macau for Patients with Relapsed Ovarian Cancer

Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, today announced its approval to commercialize ZEJULA (niraparib), an oral, once-daily poly (ADP-ribose)...

ZLAB : 31.86 (+1.24%)
GSK : 39.96 (-0.40%)
SmallCap Sentinel: As Fears Abate, an Array of Positive Factors Align for Drug Makers

The fears present in the 2018 market for drug makers... price ceilings and regulatory assaults... may have been exaggerated. In fact, a market under siege in 2018 has had a more than solid year. Recent...

ABT : 81.90 (-0.39%)
JNJ : 139.59 (-0.36%)
GSK : 39.96 (-0.40%)
INNV : 1.2500 (-16.67%)
PRGO : 43.85 (+1.55%)
Discovery Labs is Developing a $500 million Healthcare, Life Sciences and Technology Coworking Community in King of Prussia, PA

The Discovery Labs, a platform company formed by MLP Ventures, announced at BIO 2019 (Booth 4134) it is redeveloping GlaxoSmithKline's one million square foot Upper Merion West Campus and the 640,000 Innovation...

GSK : 39.96 (-0.40%)
Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options

GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.

AZN : 39.92 (+0.63%)
REGN : 311.58 (+2.08%)
GSK : 39.96 (-0.40%)
SNY : 42.52 (+0.12%)
Emergent (EBS) Wins HHS Contract to Supply VIGIV Product

Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.

EBS : 44.81 (+3.34%)
ACOR : 7.74 (+2.79%)
GSK : 39.96 (-0.40%)
SNY : 42.52 (+0.12%)
FSD Pharma Brings in World-Renowned Experts to Build Bioscience Division -- CFN Media

Seattle, Washington--(Newsfile Corp. - June 4, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication...

FSDDF : 0.1320 (-3.79%)
HUGE.CN : 0.175 (-2.78%)
GSK : 39.96 (-0.40%)
World Heart Failure Drugs Market to Witness a CAGR of 9.1% During 2019-2025 - Dominated by Novartis, GlaxoSmithKline, AstraZeneca, Bayer, and Pfizer - ResearchAndMarkets.com

The "Global Heart Failure Drugs Market - Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025" report has been added to ResearchAndMarkets.com's offering.

GSK : 39.96 (-0.40%)
Gilead Gains 6.8% YTD as HIV Franchise Maintains Momentum

Gilead (GILD) up 6.9% in the year so far on strong performance of HIV franchise and pipeline development efforts.

NVO : 51.32 (+0.71%)
GILD : 67.23 (+1.31%)
GLPG : 121.71 (+0.44%)
GSK : 39.96 (-0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade GSK with:

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Key Turning Points

2nd Resistance Point 40.29
1st Resistance Point 40.21
Last Price 39.96
1st Support Level 39.98
2nd Support Level 39.83

See More

52-Week High 42.32
Fibonacci 61.8% 40.06
Last Price 39.96
Fibonacci 50% 39.36
Fibonacci 38.2% 38.67
52-Week Low 36.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar